This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/186,468, filed June 30, 2015, and U.S. Provisional Application No. 62/328,277, filed April 27, 2016, all of which are incorporated herein by reference in their entireties. BACKGROUND OF THE INVENTION Normal control of breathing is a complex process that involves, in part, the body's interpretation and response to chemical stimuli such as carbon dioxide, pH and oxygen levels in blood, tissues and the brain. Normal breathing control is also affected by other factors such as wakefulness (i.e. , whether the patient is awake or sleeping), emotion, posture and vocalization. Within the brain medulla, there are respiratory control centers that interpret various feed-forward and feed-back signals that affect respiration by issuing commands to the muscles that perform the work of breathing. Key muscle groups are located in the abdomen, diaphragm, pharynx and thorax. Sensors located centrally and peripherally then provide input to the brain's central respiration control areas that enables response to changing metabolic requirements. For example, ventilation sufficient to meet the body's metabolic needs is maintained primarily by the body's rapid response to changes in carbon dioxide (CO2) levels. Increased CO2 levels (hypercapnia) signal the body to increase breathing rate and depth, resulting in higher blood oxygen levels and subsequent lower blood CO2 levels. Conversely, low CO2 levels (hypocapnia) can result in periods of hypopnea (decreased breathing) or, in the extreme case, apnea (no breathing) since the stimulation to breathe is diminished. There are many diseases in which loss of normal breathing control is a primary or secondary feature of the disease. Examples of diseases with a primary loss of breathing control are sleep apneas (central, mixed or obstructive; where the breathing repeatedly stops for 10 to 60 seconds) and congenital central hypoventilation syndrome. Secondary loss of breathing control may be due to chronic cardio-pulmonary diseases (e.g., heart failure, chronic bronchitis, emphysema, and impending respiratory failure), excessive weight (e.g. , obesity -hypoventilation syndrome), certain drugs (e.g., anesthetics, sedatives, sleeping aids, anxiolytics, hypnotics, alcohol, and narcotic analgesics and/or factors that affect the neurological system (e.g., stroke, tumor, trauma, radiation damage, and ALS). In chronic obstructive pulmonary diseases where the body is exposed to chronically high levels of carbon dioxide, the body adapts to the respiratory acidosis (lower pH) by a kidney mediated retention of bicarbonate, which has the effect of partially neutralizing the CCVpH respiratory stimulation. Thus, the patient is unable to mount a normal ventilatory response to changes in metabolic demand. Sleep disordered breathing is an example of where abnormalities in the control of breathing lead to a serious and prevalent disease in humans. Sleep apnea is characterized by frequent periods of no or partial breathing. Key factors that contribute to these apneas include anatomical factors (e.g., obesity), decreased hypercapnic and hypoxic ventilatory responses (e.g. , decreased response to high carbon dioxide and low oxygen levels, respectively) and loss of "wakefulness" (respiratory drive to pharyngeal dilator muscles during sleep). Apneic events result in intermittent hypoxia (and the associated oxidative stress) and eventually severe cardiovascular consequences (high blood pressure, stroke, heart attack). Estimates for U.S. individuals afflicted with conditions wherein there is compromised respiratory control include sleep apneas (15-20 millions); obesity-hypoventilation syndrome (3-5 millions); chronic heart disease (5 millions); chronic obstructive pulmonary disease (COPD)/chronic bronchitis (10 millions); drug-induced hypoventilation (2-10 millions); and mechanical ventilation weaning (0.5 million). There is a need in the art for novel compounds useful for restoring all or part of the body's normal breathing control system in response to changes in CO2 and/or oxygen levels, with minimal side effects. Further, there is a need in the art for novel compounds that are useful for restoring all or part of the body's normal breathing control system and possess suitable pharmacokinetic properties, such as oral bioavailability. Further, there is a need in the art for novel compounds that are useful for restoring all or part of the body's normal breathing control system and may be administered orally and used in a chronic or acute manner. Further, there is a need in the art for novel compounds that are useful for restoring all or part of the body's normal breathing control system and may be administered parenterally (e.g., intravenously) and used in an acute manner. The present invention addresses and meets these needs. BRIEF SUMMARY OF THE INVENTON The invention provides a compound of formula (I), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (I), wherein in (I): one of the substituents selected from the group consisting of Y1 and Y2 is selected from the group consisting of-N(R1)-L-C(R9)(R10)OH, , and and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of hydrogen and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R9 and R10 are independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; or R9 and R10 combine with the carbon atom to which they are bound so as to form an optionally substituted C3-C6 cycloalkyl group; each instance of R11 is independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; wherein a -C(R11)2-C(R11)2- group within ring b is optionally replaced by an optionally substituted 1,2-phenylene group that is fused with ring b, each occurrence of independently optionally substituted C1-C3 alkylene; m and n are independently selected from the group consisting of 1, 2, 3 and 4, such that 2<(m+n)<4; p and q are independently elected from the group consisting of 0, 1, 2, 3 and 4, such that 2<(p+q)<4; with the proviso that the alkyl group is not substituted with a hydroxy group. In certain embodiments, the compound of formula (I) is the compound of formula Ila), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (Ila), wherein in (Ila): one of the substituents selected from the group consisting of Y1 and Y2 is -L-C(R9)(R10)OH, and and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of hydrogen and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R9 and R10 are independently selected from the group consisting of hydrogen and optionally substituted Ci-C3-alkyl; or R9 and R10 combine with the carbon atom to which they are bound so as to form an optionally substituted C3-C6 cycloalkyl group; L is optionally substituted C1-C3 alkylene; and with the proviso that the alkyl group is not substituted with a hydroxy group. In certain embodiments, the compound of formula (I) is the compound of formula (lib), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (lib), wherein in (lib): one of the substituents selected from the group consisting of Y1 and Y2 is and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of H and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted;L is optionally substituted C1-C3 alkylene; and R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; each instance of R11 is independently selected from the group consisting of hydrogen and optionally substituted Ci-C3-alkyl; L is optionally substituted Ci-C3 alkylene; m and n are independently selected from the group consisting of 1, 2, 3 and 4, such that 22 desaturations after the administration of l -(2,6-bis-methylamino-8-propylainino-pyrirnido[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a). FIG. 19 depicts a graph illustrating the reduction of frequency of obstructive apneas (OA) after the administration of l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a). FIG. 20 depicts a graph illustrating the reduction of arterial oxygen content deficit after the administration of l -(2,6-bis-methylandno-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a). FIG. 21 A depicts a graph illustrating increases of airway (genioglossus, or GG) responses in rats, to evoked obstructions after the administration of l-(2,6-bis-methylandno-8-propylamino-pyrinddo[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a). FIG. 21B depicts a graph illustrating insignificant increases of diapraghm (DIA) responses, in the same rats, to evoked obstructions after the administration of 1 -(2,6-bis-methylandno-8-propylandno-pyriiTddo[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a). Red bar- Vehicle; Light blue bar- Middle dose (MD) cmpd (31a) infusion involved administering 0.008 mg/kg/min for 15 minutes (loading phase) followed by 0.002 mg/kg/min for 45 minutes (maintenance phase); Dark blue bar- High dose (HD) cmpd (31a) infusion entailed administering 0.024 mg/kg/min for 15 minutes (loading phase) followed by 0.006 mg/kg/min for 45 minutes (maintenance phase). FIG. 22 depicts a graph illustrating the increase in the upper airway (total genioglossus EMG amplitude) response to spontaneous obstructive apneas in rats after the administration of l-(2,6-bis-methylandno-8-propylandno-pyrinddo[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a). FIG. 23 depicts a graph illustrating that l-(2,6-bis-methylamino-8-propylandno-pyrimido[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a) administered by IV infusion dose-dependently increases the upper airway response (genioglossus activity) to spontaneous obstructive apneas in rats. FIG. 24 is a table illustrating that l-(2,6-bis-methylamino-8-propylarnino-pyrimido[5,4-d]pyrirnidin-4-yl amino)-2-methyl-propan-2-ol hydrochloride salt (31a) (10 mg/kg PO) does not produce effects on sleep architecture in rats. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the discovery that the compounds of the invention are orally bioavailable breathing control modulators and useful in the prevention or treatment of breathing control disorders or diseases. Further, the compounds of the invention are breathing control modulators suitable in the prevention or treatment of breathing control disorders or diseases. In certain embodiments, the compounds are orally bioavailable. In one aspect, the compounds of the invention prevent changes to the body's normal breathing control system, as a result of disorders and diseases and in response to changes in C02 and/or oxygen levels, with minimal side effects. In another aspect, the compounds of the invention decrease the incidence and severity of breathing control disturbances, such as apneas. In yet another aspect, the compounds of the invention decrease the incidence of apneic events and/or decrease the duration of apneic events. In yet another aspect, the compounds of the invention have good metabolic stability and oral bioavailability. In yet another aspect, the compounds of the invention do not interfere with the effectiveness of therapies that may cause changes to breathing control, such as opioid analgesia. Such breathing control-altering therapies benefit from administration of agents that support or restore normal breathing function. In certain embodiments, the breathing control disorder or disease is selected from, but is not limited to, the group consisting of respiratory depression, sleep apnea, apnea of prematurity, obesity -hypoventilation syndrome, primary alveolar hypoventilation syndrome, dyspnea, altitude sickness, hypoxia, hypercapnia, chronic obstructive pulmonary disease (COPD) and sudden infant death syndrome (SIDS). In other embodiments, the respiratory depression is caused by an anesthetic, a sedative, a sleeping aid, an anxiolytic agent, a hypnotic agent, alcohol or a narcotic. In yet other embodiments, the respiratory depression is caused by genetic factors as manifested in, but not limited to, congenital central hypoventilation syndrome. In yet other embodiments, the respiratory depression is caused by neurological conditions such as, but not limited to, Alzheimer's disease, Parkinson's disease, stroke, Duchenne muscular dystrophy, and brain and spinal cord traumatic injury. Definitions As used herein, each of the following terms has the meaning associated with it in this section. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in animal pharmacology, pharmaceutical science, separation science and organic chemistry are those well-known and commonly employed in the art. In a non-limiting embodiment, the following terminology used to report blood gas measurements is well known to those skilled in the art and may be defined as such: minute ventilation (MV) is a measure of breathing volume per unit time and is given herein as mL/min; pCC>2 is partial pressure of carbon dioxide (gas) in (arterial) blood measured in mm Hg (millimeters of Hg); pC>2 is partial pressure of oxygen (gas) in (arterial) blood measured in mmHg (millimeters of Hg); SaC>2 is the percentage of oxyhemoglobin saturation (oxygen gas bound to hemoglobin) that correlates to the percentage of hemoglobin binding sites in the bloodstream occupied by oxygen; end-tidal CO2 is the measurement of exhaled carbon dioxide gas as detected using calorimetry, capnometry, or capnography techniques. As used herein, the articles "a" and "an" refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. As used herein, the term "about" is understood by persons of ordinary skill in the art and varies to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term "about" is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. In one aspect, the terms "co-administered" and "co-administration" as relating to a subject refer to administering to the subject a compound of the invention or salt thereof along with a compound that may also treat breathing control disorders and/or with a compound that is useful in treating other medical conditions but which in themselves may alter breathing control. In certain embodiments, the co-administered compounds are administered separately, or in any kind of combination as part of a single therapeutic approach. The co-administered compound may be formulated in any kind of combinations as mixtures of solids and liquids under a variety of solid, gel, and liquid formulations, and as a solution. As used herein, the term "CYP450" as applied to enzymes refers to cytochrome P450 family of enzymes. As used herein, a "disease" is a state of health of a subject wherein the subject cannot maintain homeostasis, and wherein if the disease is not ameliorated then the subject's health continues to deteriorate. As used herein, a "disorder" in a subject is a state of health in which the subject is able to maintain homeostasis, but in which the subject's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the subject's state of health. As used herein, the term "ED50" refers to the effective dose of a formulation that produces 50% of the maximal effect in subjects that are administered that formulation. As used herein, an "effective amount," "therapeutically effective amount" or "pharmaceutically effective amount" of a compound is that amount of compound that is sufficient to provide a beneficial effect to the subject to which the compound is administered. "Instructional material," as that term is used herein, includes a publication, a recording, a diagram, or any other medium of expression that can be used to communicate the usefulness of the composition and/or compound of the invention in a kit. The instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the invention or be shipped together with a container that contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Delivery of the instructional material may be, for example, by physical delivery of the publication or other medium of expression communicating the usefulness of the kit, or may alternatively be achieved by electronic transmission, for example by means of a computer, such as by electronic mail, or download from a website. As used herein, the term "pharmaceutical composition" or "composition" refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a subject. As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound useful within the invention, and is relatively non-toxic, i.e. , the material may be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained. As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the subject such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the subject. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the subject. Supplementary active compounds may also be incorporated into the compositions. The "pharmaceutically acceptable carrier" may further include a pharmaceutically acceptable salt of the compound useful within the invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference. As used herein, the language "pharmaceutically acceptable salt" refers to a salt of the administered compound prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic acids, inorganic bases, organic acids, inorganic bases, solvates, hydrates, and clathrates thereof. The term "prevent," "preventing" or "prevention," as used herein, means avoiding or delaying the onset of symptoms associated with a disease or condition in a subject that has not developed such symptoms at the time the administering of an agent or compound commences. Disease, condition and disorder are used interchangeably herein. By the term "specifically bind" or "specifically binds," as used herein, is meant that a first molecule preferentially binds to a second molecule (e.g. , a particular receptor or enzyme), but does not necessarily bind only to that second molecule. As used herein, a "subject" may be a human or non-human mammal or a bird. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. Preferably, the subject is human. The term "treat," "treating" or "treatment," as used herein, means reducing the frequency or severity with which symptoms of a disease or condition are experienced by a subject by virtue of administering an agent or compound to the subject. As used herein, the term "alkyl," by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e. , Ci-Cio means one to ten carbon atoms) and includes straight, branched chain, or cyclic substituent groups. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, fert-butyl, pentyl, neopentyl, hexyl, and cyclopropylmethyl. Most preferred is (Ci-Ce)alkyl, such as, but not limited to, ethyl, methyl, isopropyl, isobutyl, ft-pentyl, w-hexyl and cyclopropylmethyl. As used herein, the term "alkylene" by itself or as part of another substituent means, unless otherwise stated, a straight or branched hydrocarbon group having the number of carbon atoms designated (i.e. , Ci-Cio means one to ten carbon atoms) and includes straight, branched chain, or cyclic substituent groups, wherein the group has two open valencies. Examples include methylene, 1,2-ethylene, 1,1 -ethylene, 1,1 -propylene, 1,2-propylene and 1,3-propylene. As used herein, the term "cycloalkyl," by itself or as part of another substituent means, unless otherwise stated, a cyclic chain hydrocarbon having the number of carbon atoms designated (i.e. , C3-C6 means a cyclic group comprising a ring group consisting of three to six carbon atoms) and includes straight, branched chain or cyclic substituent groups. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Most preferred is (C3-Ce)cycloalkyl, such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. As used herein, the term "alkenyl," employed alone or in combination with other terms, means, unless otherwise stated, a stable mono-unsaturated or di-unsaturated straight chain or branched chain hydrocarbon group having the stated number of carbon atoms. Examples include vinyl, propenyl (or allyl), crotyl, isopentenyl, butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and the higher homologs and isomers. A functional group representing an alkene is exemplified by -CH2-CH=CH2. As used herein, the term "alkynyl," employed alone or in combination with other terms, means, unless otherwise stated, a stable straight chain or branched chain hydrocarbon group with a triple carbon-carbon bond, having the stated number of carbon atoms. Non-limiting examples include ethynyl and propynyl, and the higher homologs and isomers. The term "propargylic" refers to a group exemplified by -CH2-C≡CH. The term "homopropargylic" refers to a group exemplified by -CH2CH2-C≡CH. The term "substituted propargylic" refers to a group exemplified by -CR2-C≡CR, wherein each occurrence of R is independently H, alkyl, substituted alkyl, alkenyl or substituted alkenyl, with the proviso that at least one R group is not hydrogen. The term "substituted homopropargylic" refers to a group exemplified by -CR2CR2-C≡CR, wherein each occurrence of R is independently H, alkyl, substituted alkyl, alkenyl or substituted alkenyl, with the proviso that at least one R group is not hydrogen. As used herein, the term "substituted alkyl," "substituted cycloalkyl," "substituted alkenyl" or "substituted alkynyl" means alkyl, cycloalkyl, alkenyl or alkynyl, as defined above, substituted by one, two or three substituents selected from the group consisting of halogen, alkoxy, tetrahydro-2-H-pyranyl, -NH2, -N(CH3)2, (1-methyl-imidazol-2-yl), pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, -C(=0)OH, trifluoromethyl, -C≡N, -C(=0)0(Ci-C4)alkyl, -C(=0)NH2, -C(=0)NH(Ci-C4)alkyl, -S02NH2, -C(=NH)NH2, and -N02, preferably containing one or two substituents selected from halogen, -OH, alkoxy, -NH2, trifluoromethyl, -N(CH3)2, and -C(=0)OH, more preferably selected from halogen, alkoxy and -OH. Examples of substituted alkyls include, but are not limited to, 2,2-difluoropropyl, 2-carboxycyclopentyl and 3-chloropropyl. In certain embodiments, the substituted alkyl is not substituted with a hydroxy group. As used herein, the term "alkoxy" employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy (isopropoxy) and the higher homologs and isomers. Preferred are (Ci-C3)alkoxy, such as, but not limited to, ethoxy and methoxy. As used herein, the term "halo" or "halogen" alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably, fluorine, chlorine, or bromine, more preferably, fluorine or chlorine. As used herein, the term "heteroalkyl" by itself or in combination with another term means, unless otherwise stated, a stable straight or branched chain alkyl group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatom(s) may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the fragment to which it is attached, as well as attached to the most distal carbon atom in the heteroalkyl group. Examples include: -0-CH2-CH2-CH3, -CH2-CH2-CH2-OH, -CH2-CH2-NH-CH3, -CH2-S-CH2-CH3, and -CH2CH2-S(=0)-CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3, or -CH2-CH2-S-S-CH3. As used herein, the term "heteroalkenyl" by itself or in combination with another term means, unless otherwise stated, a stable straight or branched chain monounsaturated or di -unsaturated hydrocarbon group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. Up to two heteroatoms may be placed consecutively. Examples include -CH=CH-0-CH3, -CH=CH-CH2-OH, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, and -CH2-CH=CH-CH2-SH. As used herein, the term "aromatic" refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e. having (4n+2) delocalized π (pi) electrons, where n is an integer. As used herein, the term "aryl," employed alone or in combination with other terms, means, unless otherwise stated, a carbocyclic aromatic system containing one or more rings (typically one, two or three rings) wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene. Examples include phenyl, anthracyl, and naphthyl. Preferred are phenyl and naphthyl, most preferred is phenyl. As used herein, the term "aryl-(Ci-C3)alkyl" means a functional group wherein a one to three carbon alkylene chain is attached to an aryl group, e.g. , -CH2CH2-phenyl or -CH2-phenyl (benzyl). Preferred is aryl-CH2- and aryl-CH(CH3)-. The term "substituted aryl-(Ci-C3)alkyl" means an aryl-(Ci-C3)alkyl functional group in which the aryl group is substituted. Preferred is substituted aryl(CH2)-. Similarly, the term "heteroaryl-(Ci-C3)alkyl" means a functional group wherein a one to three carbon alkylene chain is attached to a heteroaryl group, e.g. , -CH2CH2-pyridyl. Preferred is heteroaryl-(CH2)-. The term "substituted heteroaryl-(Ci-C3)alkyl" means a heteroaryl-(Ci-C3)alkyl functional group in which the heteroaryl group is substituted. Preferred is substituted heteroaryl-(CH2)-. As used herein, the term "heterocycle" or "heterocyclyl" or "heterocyclic" by itself or as part of another substituent means, unless otherwise stated, an unsubstituted or substituted, stable, mono- or multi-cyclic heterocyclic ring system that consists of carbon atoms and at least one heteroatom selected from the group consisting of N, O, and S, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic system may be attached, unless otherwise stated, at any heteroatom or carbon atom that affords a stable structure. A heterocycle may be aromatic or non-aromatic in nature. In certain embodiments, the heterocycle is a heteroaryl. As used herein, the term "heteroaryl" or "heteroaromatic" refers to a heterocycle having aromatic character. A poly cyclic heteroaryl may include one or more rings that are partially saturated. Examples include tetrahydroquinoline and 2,3-dihydrobenzofuryl. Examples of non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazoline, pyrazolidine, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1 , 2,3, 6-tetrahydropyri dine, 1 ,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dioxane, 1 ,3-dioxane, homopiperazine, homopiperidine, 1,3-dioxepane, 4,7-dihydro-l ,3-dioxepin and hexamethyleneoxide. Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl (such as, but not limited to, 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,3,4-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1 ,2,3-oxadiazolyl, 1,3,4-thiadiazolyl and 1 ,3,4-oxadiazolyl. Examples of poly cyclic heterocycles include indolyl (such as, but not limited to, 3-, 4-, 5-, 6- and 7-indolyl), indolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (such as, but not limited to, 1 - and 5-isoquinolyl), 1 ,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (such as, but not limited to, 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1,8-naphthyridinyl, 1,4-benzodioxanyl, coumarin, dihydrocoumarin, 1 ,5-naphthyridinyl, benzofuryl (such as, but not limited to, 3-, 4-, 5-, 6- and 7-benzofuryl), 2,3-dihydrobenzofuryl, 1 ,2-benzisoxazolyl, benzothienyl (such as, but not limited to, 3-, 4-, 5-, 6-, and 7-benzothienyl), benzoxazolyl, benzothiazolyl (such as, but not limited to, 2-benzothiazolyl and 5-benzothiazolyl), purinyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl, and quinolizidinyl. The aforementioned listing of heterocyclyl and heteroaryl moieties is intended to be representative and not limiting. As used herein, the term "substituted" means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group. For aryl, aryl-(Ci-C3)alkyl and heterocyclyl groups, the term "substituted" as applied to the rings of these groups refers to any level of substitution, namely mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. In certain embodiments, the substituents vary in number between one and four. In other embodiments, the substituents vary in number between one and three. In yet other embodiments, the substituents vary in number between one and two. In yet other embodiments, the substituents are independently selected from the group consisting of C1-6 alkyl, -OH, C1-6 alkoxy, halo, amino, acetamido and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic, with straight being preferred. The following abbreviations are used herein: ABG: arterial blood gas; AcOH: acetic acid; AS V: adaptive servo ventilation; AUC: area under (the) curve; BOP: (benzotriazol-l-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; BiPAP: bi-level positive airway pressure; nBuOH: «-butanol; C: carbon atom or elemental carbon; 1 C NMR: carbon-13 nuclear magnetic resonance; CHCI3: chloroform; CDCI3: chloroform-d; CH2CI2: dichloromethane or methylene dichloride; CPAP: continuous positive airway pressure; CSA: central sleep apnea; DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene; DCM: dichloromethane or methylene dichloride; DIA: diaphragm (muscle); DIPEA: N,N-diisopropylethylamine; DMAc: N,N-dimethylacetamide; DMSO: dimethylsulfoxide; DMSO-de: dimethylsulfoxide-de; DSC: differential scanning calorimetry; EPAP: expiratory positive airway pressure; EtOAc: ethyl acetate; EtOH: ethanol; Et20: (di)ethyl ether; f: frequency (of respiration); F (%): bioavailability (percent); FID: flame ionization detector; GG: genioglossus; H: hydrogen atom or elemental hydrogen; XH NMR: proton or hydrogen-1 nuclear magnetic resonance; HC1: hydrochloric acid or a hydrochloride salt; HDPE: high-density polyethylene; hERG: human Ether-a-go-go Related Gene (Kv 11.1 ion channel); H2SO4: sulfuric acid; HLM: human liver microsomes; HPLC: high pressure liquid chromatography; ICU: intensive care unit; IPA: isopropanol (or 2-propanol); IPAP: inspiratory positive airway pressure; kPa: kilopascal; LCMS: liquid chromatography -mass spectrometry; LOQ: limit of quantification; m: multiplet; MAP: mean arterial blood pressure; mbar: millibar (0.001 bar); MBP: mean blood pressure; MTBE: methyl fert-butyl ether; MeCN or CH3CN: acetonitrile; MEK: methyl ethyl ketone; MeOH or CH3OH: methanol; min: minute; mL (or ml): milliliter; MP: melting point; mpk: mg/kg; MV: inute volume (synonymous with VE); ms: milli-second; MS: mass spectrometry; N: nitrogen atom or elemental nitrogen; NaCl: sodium chloride; NaHCC : sodium bicarbonate; NaOH: sodium hydroxide; Na2SC>4: sodium sulfate; NAVA: neurally adjusted ventilatory assist; NIPPV: non-invasive positive pressure ventilation; NMR: nuclear magnetic resonance; O: oxygen atom or elemental oxygen; OA: obstructive apnea; PA: propargylamine (propargylic amine); PAV: proportional assist ventilation; PE or pet ether: petroleum ether; PEG: polyethylene glycol; PET: positron emission topography; ppm: part per million; q: quartet; RLM: rat liver microsomes; RR: respiratory rate; rt: room (ambient) temperature; s: singlet; Sp02: arterial oxygen saturation; std: standard; t: triplet; THF: tetrahydrofuran; TV: tidal volume; UPLC: ultra performance liquid chromatography; VE: minute (expired) volume (synonymous with MV); XRPD: x-ray powder diffraction (spectrum); δ (delta): delta (ppm); (μΐ): microliter. Throughout this disclosure, various aspects of the invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range and, when appropriate, partial integers of the numerical values within ranges. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range. Compounds and Compositions The invention includes a compound of formula (I), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (I), wherein in (I): one of the substituents selected from the group consistin of Y1 and Y2 is selected from the roup consisting of -N(R1)-L-C(R9)(R10)OH, and , and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of hydrogen and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R9 and R10 are independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; or R9 and R10 combine with the carbon atom to which they are bound so as to form an optionally substituted C3-C6 cycloalkyl group; each instance of R11 is independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; wherein a -C(Rn)2-C(Rn)2- group within ring b is optionally replaced by an optionally substituted 1,2-phenylene group that is fused with ring b, each occurrence of L is independently optionally substituted C1-C3 alkylene; m and n are independently selected from the group consisting of 1, 2, 3 and 4, such that 2≤ m+n<4; p and q are independently selected from the group consisting of 0, 1 , 2, 3 and 4, such that 2 p+q<4; with the proviso that the alkyl group is not substituted with a hydroxy group. In certain embodiments, the compound of formula (I) is the compound of formula (Ila), or a salt, solvate enantiomer, diastereoisomer or tautomer thereof: (Ila), wherein in (Ila): one of the substituents selected from the group consisting of Y1 and Y2 is -L-C(R9)(R10)OH, and and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of hydrogen and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R9 and R10 are independently selected from the group consisting of hydrogen and optionally substituted Ci-C3-alkyl; or R9 and R10 combine with the carbon atom to which they are bound so as to form an optionally substituted C3-C6 cycloalkyl group; L is optionally substituted C1-C3 alkylene; and with the proviso that the alkyl group is not substituted with a hydroxy group. In certain embodiments, the compound of formula (I) is the compound of formula (lib), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (lib), wherein in (lib): one of the substituents selected from the group consisting of Y1 and Y2 is and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of H and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted;L is optionally substituted C1-C3 alkylene; and R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; each instance of R11 is independently selected from the group consisting of hydrogen and optionally substituted Ci-C3-alkyl; L is optionally substituted C1-C3 alkylene; m and n are independently selected from the group consisting of 1, 2, 3 and 4, such that 2≤ m+n<4; with the proviso that the alkyl group is not substituted with a hydroxy group. In certain embodiments, the compound of formula (I) is the compound of formula (lie), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (He), wherein in (lie): one of the substituents selected from the group consisting of Y1 and Y2 is , and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of hydrogen and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R9 and R10 are independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; or R9 and R10 combine with the carbon atom to which they are bound so as to form an optionally substituted C3-C6 cycloalkyl group; each instance of R11 is independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; wherein a -C(Rn)2-C(Rn)2- group within ring b is optionally replaced by an optionally substituted 1,2-phenylene group that is fused with ring b each occurrence of L is independently optionally substituted C1-C3 alkylene; p and q are s independently elected from the group consisting of 0, 1, 2, 3 and 4, such that 2≤ p+q<4; with the proviso that the alkyl group is not substituted with a hydroxy group. In certain embodiments, each occurrence of the alkyl group is independently optionally substituted with one or more independently selected from the group consisting of Ci-C6 alkyl, F, CI, Br, I, and CN. In certain embodiments, each occurrence of the cycloalkyl, alkenyl or alkynyl group is independently optionally substituted with one or more independently selected from the group consisting of C1-C6 alkyl, F, CI, Br, I, and CN. In certain embodiments, each occurrence of the phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted with one or more independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, hydroxy, F, CI, Br, I, nitro, -NH2, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)( Ci-C6 alkyl), -S(=O)0. 2(Ci-C6 alkyl), -C(=0)OH and alkyl. In certain embodiments, R1, R5 and R7 are H. In other embodiments, R1, R5 and R7 are H; and R6 and R8 are independently optionally substituted Ci-Ce alkyl. In yet other embodiments, R1, R5 and R7 are H; and R6 and R8 are independently optionally substituted arylalkyl. In yet other embodiments, R1, R5 and R7 are H; and R6 and R8 are independently optionally substituted alkenyl. In yet other embodiments, R1, R5 and R7 are H; and R6 and R8 are independently optionally substituted alkynyl. In certain embodiments, R1, R5 and R7 are independently optionally substituted Ci-C3-alkyl. In other embodiments, R1, R5 and R7 are independently optionally substituted Ci-C3-alkyl; and R6 and R8 are independently optionally substituted alkyl. In yet other embodiments, R1, R5 and R7 are independently optionally substituted Ci-C3-alkyl; and R6 and R8 are independently optionally substituted arylalkyl. In yet other embodiments, R1, R5 and R7 are independently optionally substituted Ci-C3-alkyl; and R6 and R8 are independently optionally substituted alkenyl. In yet other embodiments, R1, R5 and R7 are independently optionally substituted Ci-C3-alkyl; and R6 and R8 are independently optionally substituted alkynyl. In certain embodiments, R1, R5 and R7 are H; and R9 and R10 are H. In other embodiments, R1, R5 and R7 are H; R9 and R10 are H; and R6 and R8 are independently optionally substituted alkyl. In yet other embodiments, R1, R5 and R7 are H; R9 and R10 are H; and R6 and R8 are independently optionally substituted arylalkyl. In yet other embodiments, R1, R5 and R7 are H; R9 and R10 are H; and R6 and R8 are independently optionally substituted alkenyl. In yet other embodiments, R1, R5 and R7 are H; R9 and R10 are H; and R6 and R8 are independently optionally substituted alkynyl. In certain embodiments, R1, R5 and R7 are H; and R9 and R10 are CH3. In other embodiments, R1, R5 and R7 are H; R9 and R10 are CH3; and R6 and R8 are independently optionally substituted alkyl. In yet other embodiments, R1, R5 and R7 are H; R9 and R10 are CH3; and R6 and R8 are independently optionally substituted arylalkyl. In yet other embodiments, R1, R5 and R7 are H; R9 and R10 are CH3; and R6 and R8 are independently optionally substituted alkenyl. In yet other embodiments, R1, R5 and R7 are H; R9 and R10 are CH3; and R6 and R8 are independently optionally substituted alkynyl. In certain embodiments, R1, R5 and R7 are H; R9 is H; and R10 is CH3. In other embodiments, R1, R5 and R7 are H; R9 is H; R10 is CH3; and R6 and R8 are independently optionally substituted alkyl. In yet other embodiments, R1, R5 and R7 are H; R9 is H; R10 is CH3; and R6 and R8 are independently optionally substituted arylalkyl. In yet other embodiments, R1, R5 and R7 are H; R9 is H; R10 is CH3; and R6 and R8 are independently optionally substituted alkenyl. In yet other embodiments, R1, R5 and R7 are H; R9 is H; R10 is CH3; and R6 and R8 are independently optionally substituted alkynyl. In certain embodiments, each occurrence of the alkyl group is independently optionally substituted with one or more independently selected from the group consisting of Ci-C6 alkyl, F, CI, Br, I, and CN. In certain embodiments, each occurrence of the cycloalkyl, alkenyl or alkynyl group is independently optionally substituted with one or more independently selected from the group consisting of C1-C6 alkyl, F, CI, Br, I, and CN. In certain embodiments, each occurrence of the phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted with one or more independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, hydroxy, F, CI, Br, I, nitro, -NH2, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)( Ci-C6 alkyl), -S(=O)0- 2(Ci-C6 alkyl), -C(=0)OH and alkyl. In certain embodiments, R1 is selected from the group consisting of H, CH3 and propyl. In certain embodiments, R2 is selected from the group consisting of CH3, ethyl, CH2CHF2 and CH2CF3. In certain embodiments, R5 is selected from the group consisting of H and CH The 3 . In certain embodiments, R6 is selected from the group consisting of CH3, ethyl, propyl, CH2CHF2, CH2CF3, CH2(cyclopropyl), sec-Bu, CH2(2-pyrimidine), CH2CH=CH2 and CH2C(CH3)=CH2. In certain embodiments, R7 is selected from the group consisting of H and CH The 3 . In certain embodiments, R8 is selected from the group consisting of CH3, ethyl, propyl, CH2CHF2, CH2CF3, CH2(cyclopropyl), sec-Bu, CH2(2-pyrimidine), benzyl, CH2CH2OCH3 and CH2C≡CH. In certain embodiments, R9 and R10 are independently selected from the group consisting H, CH3, ethyl and CF3. In certain embodiments, R11 is selected from the group consisting of H and a fused phenylene ring. In certain embodiments, L is selected from the group consisting of methylene, methyl substituted methylene, dimethyl substituted methylene and ethylene. In certain embodiments, m and n are independently selected from the group consisting of 1 and 2. In certain embodiments, p and q are independently selected from the group consisting of 0, 3 and 4. 1 is selecte the group consisting In certain embodiments, Y is selected from the group consisting In certain embodiments, the compound of formula (I) is selected from the group consisting of: 2- (2,6-Bis-methylarnino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylam (4); 2-[(2,6-Bis-methylarnino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl)-met^^ ethanol (6); 3-(2,6-Bis-methylarnino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylam propan-l-ol (8); l-(2,6-Bis-methylarnino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-2-ol (10); (S)-l-(2,6-Bis-methylarnino-8-propylamino-pyrirnido[5,4-d]pyrimidin-4-ylamino)-propan-2-ol (12); (R)-l-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-propan-2-ol (14); 2-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-2-methyl-propan-l-ol (16); (S)-2-(2,6-Bis-methylarnino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylami (18); (R)-2-(2,6-Bis-methylainino-8-propylainino-pyri l-ol (20); 3- (2,6-Bis-methylarnino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylam trifluoro-propan-2-ol (22); l-(2,6-Bis-methylarnino-8-propylamino-pyrirnido[5,4-d]pyrimidin-4-ylamino)-butan-2-ol (24); 3-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-butan-2-ol (26); 2-(2,6-Bis-ethylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-ethanol (27); 2-[8-Propylamino-2,6-bis-(2,2,2-trifluoro-ethylamino)-pyrimido[5,4-d]pyrimidin-4-ylamino]-ethanol (28); l-(2,6-Bis-methylainino-8-propylamino-pyrirnido[5,4-d]pyri (31); l-(2,6-Bis-ethylarnino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylam propan-2-ol (32); l-[2,6-Bis-(2,2-difluoro-ethylamino)-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino]-2-methyl-propan-2-ol (33); 2-Methyl-1 8-propylamino-2,6-bis-(2,2,2-trifluoro-ethylamino)-pyrimido[5,4-d]pyrimidin-4-ylamino]-propan-2 (34); 1- [8-(2,2-difluoro-ethylainino)-2,6-bis-methy 2- methyl-propan-2-ol (36); l-{2,6-bis-methylaniino-8-[(pyrimidin-2-ylmethyl)-amino]-pyrimido[5,4-d]pyrimidin-4-ylamino}-2-methyl-propan-2-ol (38); 1 8-((R)-sec-butylamino)-2,6-bis-methylaniino-pyrimido[5,4-d]-pyrimidin-4-ylamino]-2-methyl-propan-2-o (40); l-[8-((S)-sec-butylamino)-2,6-bis-methylamin^ propan-2-ol (42); l-(8-benzylamino-2,6-bis-methylarnino-pyrimido[5,4-d]pyrimidin-4-ylamino)-2-methyl-propan-2-ol (44); l-[8-(cyclopropylmethyl-amino)-2,6-bis-methylamino- pyrimido[5,4-d]pyrimidin-4-ylamino]-2-methyl-propan-2-ol (46) ; l-[8-(2,2-difluoro-ethylamino)-2,6-bis-ethylamino-pyrimido[5,4-d]pyrimidin-4-ylamino]-2-meth^ (47) ; 2-methyl-l-(2,6,8 ris-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propa^ (48) ; 2-methyl-l-(2,6,8 ris-ethylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-2-ol (49) ; 2-(2,6,8 ris-methylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-ethanol (52); 2-[8-(cyclopropylmethyl-amino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylam ethanol (54); 2-[8-(2-methoxy-ethylamino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylamino]-ethanol (56); 2-(2,6-bis-methylamino-8-prop-2-ynylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-ethanol (58); 2-[8-(2,2-difluoro-ethylamino)-2,6-bis-methylamino-pyrimido [5, 4-d]-pyrimidin-4-ylamino] -ethanol (60); 2-[2,6-bis-methylamino-8-(2,2,2-trifluoro-ethylamino)-pyrimido[5,4-d]pyrimidin-4-ylamino]-ethanol (62); 2-(8-benzylamino-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-ethanol (64); 3-(8-ethylamino-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-l-ol (67); l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl)-pyrrolidin-3-ol (71); l-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-methyl]-cyck (72); l-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-yl)-methyl-amino]-propan-2-ol (73); 3-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-methyl]-pentan-3-ol (74); l-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl)-methyl-amino]-2-methyl-propan-2-ol (76); (lR,2S)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-indan-2-ol (77); (l S,2S)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino indan-2-ol (78); (l S,2R)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-indan-2-ol (79); (lR,2R)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-indan-2-ol (80); (2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-indan-l-ol (81); (lR,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-cyclohexanol (82); (lS,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-cyclohexanol (83); (l S,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino cyclohexanol (84); (lR,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-cyclohexanol (85); (1 S,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-cyclopentanol (86); (lR,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-cyclopentanol (87); 2-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylam ethanol (90); 2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- ethanol (91); 2-(6-dimethylamino-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-ethanol (92); l -(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-2-methyl-propan-2-ol (94); l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-propan-2-ol (95); l -[(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-yl)-methyl-amino]-2-methyl-propan-2-ol (96); l-[(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-yl)-methyl-amino]-propan-2-ol (97); l-[6-((R)-sec-butylairrino)-4,8-bis-meth^ 2-methyl-propan-2-ol (99); (R)-l-[6-((R)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]-propan-2-ol (100); (S)-l-[6-((R)-sec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]-propan-2-ol (101); \ -[6-((S)-sec-butylamino)-4,8-bis-methylairrino-pyrim ol (103); (R)-l -[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]-propan-2-ol (104); (S)-l-[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]-propan-2-ol (105); l-[6-(2,2-difluoro-ethylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]-2-methyl-propan-2-ol (107); l- {4,8-bis-methylamino-6-[(pyrimidin-2-ylmethyl)-amino]-pyrimido[5,4-d]pyrimidin-2-ylam methyl-propan-2-ol (109); 3-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-y lamino)- 1 , 1, 1 -trifluoro-propan-2-ol (111); (S)- 1 -(4, 8-bis-methy lamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (113); (R)-l -(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (115); l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2-ol (117); 3-(4,8-Bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2-ol (119); (lR,2S)-l -(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-indan-2-ol (123); (l S,2S)-l -(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-indan-2-ol (125); (l S,2R)-l -(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-indan-2-ol (127); ( 1R,2R)-1 -(4, 8-bis-methy lamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-indan-2-ol (129); (lR,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-cyclohexanol (131); (l S,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-cyclohexanol (133); (1 S,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-cyclohexanol (135); (lR,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-cyclohexanol (137); (1 S,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-cyclopentanol (139); (lR,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclopentanol (141); (S)-l-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]-propan-2-ol (142); (S)-l-(6-allylamino-4,8-bis-methylanTino-pyrinTido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (143); (R)-l-[6-(cyclopropylmethyl-ainino)-4,8-bis-methylainm^ propan-2-ol (144); (R)-l-(6-allylanTino-4,8-bis-methylanTino-pyrinTido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (145); l-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]-butan-2-ol (146); l-(6-ethylamino-4,8-bis-methylanTino-pyrinTido[5,4-d]pyrimidin-2-ylamino)-butan-2-ol (147); 2-methyl-l-(4,6,8-tris-methylanTino-pyrinTido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (149); 2-(6-allylamino-4,8-bis-methylanTino-pyrinTido[5,4-d]pyrimidin-2-ylamino)-ethanol (154); (S)-l-[(6-allylamino-4,8-bis-methylanTino-pyrinTido[5,4-d]-pyrinTidin-2-yl)-propyl-aniino]-propan-2-ol (155); (S)-1 (6-allylamino-4,8-bis-methylainino-pyrirn ^ propan-2-ol (156); (R)-l-[6-(2-methyl-allylanTino)-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino]-propan-2-ol (158); (S)-l-[6-(2-methyl-allylamino)-4,8-bis-methylanTino-pyrimido[5,4-d]-pyrimidin-2-ylamino]-propan-2-ol (159); 2-(4,8-bis-ethylanTino-6-propylanTino-pyrinTido[5,4-d]pyrinTidin-2-ylamino)-ethanol (162); l-(4,8-bis-ethylanTino-6-propylanTino-pyrinTido[5,4-d]pyrinTidin-2-ylanTino)-2-methyl-propan- (163); (S)-l-(4,6,8-Tris-ethylanTino-pyrinTido[5,4-d]pyrinTidin-2-ylamino)-propan-2-ol (165); (S)-l-(4,8-bis-ethylainino-6-propylainm^ (166); (R) -L (4,6,8-risk ethylanTino-pyrinTido [5,4-d] pyrinTidin-2-ylanTino) -propan-2-ol (168); (R) -L (4,8-bis-ethylainino-6-^ propylainm (169); (R)-l-[4,8-bis-ethylanTino-6-(2-methyl-allylanTino)-pyrimido[5,4-d]-pyriniidin-2-ylamino]-propan-2-ol (174); (S)-l-[4,8-bis-ethylamino-6-(2-methyl-allylamino)-pyrimido[5,4-d]-pyrimidin-2-ylamino]-propan-2-ol (175); a salt, solvate, enantiomer, diastereoisomer or tautomer thereof; and any combinations thereof. What is claimed: 1. A compound of formula (I), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (I), wherein in (I): one of the substituents selected from the group consistin of Y1 and Y2 is selected from the roup consisting of -N(R1)-L-C(R9)(R10)OH and , and the other substituent is -N(R )R ; R1, R5 and R7 are independently selected from the group consisting of hydrogen and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R9 and R10 are independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; or R9 and R10 combine with the carbon atom to which they are bound so as to form an optionally substituted C3-C6 cycloalkyl group; each instance of R11 is independently selected from the group consisting of H and optionally substituted Ci-C3-alkyl; wherein a -C(Rn)2-C(Rn)2- group within ring b is optionally replaced by an optionally substituted 1,2-phenylene group that is fused with ring b, each occurrence of independently optionally substituted C1-C3 alkylene; m and n are independently selected from the group consisting of 1, 2, 3 and 4, such that 2<(m+n)<4; p and q are independently elected from the group consisting of 0, 1, 2, 3 and 4, such that 2≤(p+q)≤4; with the proviso that the alkyl group is not substituted with a hydroxy group. 2. The compound of claim 1, wherein the compound of formula (I) is the compound of formula (Ila), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (Ila), wherein in (Ila): one of the substituents selected from the group consisting of Y1 and Y2 is -L-C(R9)(R10)OH, and and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of hydrogen and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; R9 and R10 are independently selected from the group consisting of hydrogen and optionally substituted Ci-C3-alkyl; or R9 and R10 combine with the carbon atom to which they are bound so as to form an optionally substituted C3-C6 cycloalkyl group; L is optionally substituted C1-C3 alkylene; and with the proviso that the alkyl group is not substituted with a hydroxy group. 3. The compound of claim 1, wherein the compound of formula (I) is the compound of formula (lib), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: (lib), wherein in (lib): one of the substituents selected from the group consisting of Y1 and Y2 is and the other substituent is -N(RX)R2; R1, R5 and R7 are independently selected from the group consisting of H and optionally substituted C1-C3 alkyl; R2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted;L is optionally substituted C1-C3 alkylene; and R6 and R8 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, phenylalkyl, aryl, arylalkyl, heteroarylalkyl or heteroaryl group is independently optionally substituted; each instance of R11 is independently selected from the group consisting of hydrogen and optionally substituted Ci-C3-alkyl; L is optionally substituted C1-C3 alkylene; m and n are independently selected from the group consisting of 1, 2, 3 and 4, such that 2-toluenesulfonic, cyclohexylaminosulfonic, β-hydroxybutyric, salicylic, galactaric and galacturonic, and any combinations thereof. 13. At least one crystalline salt of l-(2,6-Bis-methylamino-8-propylarnino-pyrirnido[5,4-d]pyrirnidin-4-yl amino)-2-methyl-propan-2-ol (31) selected from the group consisting of: (xiii) Crystalline hydrochloride salt (31a), with a XRPD spectrum as per FIG. 3A; XRPD peaks as per FIG. 3B; and/or DSC spectrum as per FIG. 3C; (xiv) Crystalline bis-hydrochloride salt (31b), with a XRPD spectrum as per FIG. 4A; XRPD peaks as per FIG. 4B; and/or DSC spectrum as per FIG. 4C; (xv) Crystalline hydrogen malonate salt (31c), with a XRPD spectrum as per FIG. 5A; XRPD peaks as per FIG. 5B; and/or DSC spectrum as per FIG. 5C; (xvi) Crystalline hydrogen maleinate salt Form Male-A (31d-l), with a XRPD spectrum as per FIG. 6A; XRPD peaks as per FIG. 6B; and/or DSC spectrum as per FIG. 6C; (xvii) Crystalline hydrogen maleinate salt Form Male-B (31d-2), with a XRPD spectrum as per FIG. 7A; XRPD peaks as per FIG. 7B; and/or DSC spectrum as per FIG. 7C; (xviii) Crystalline hydrogen fumarate salt (31e), with a XRPD spectrum as per FIG. 8A; XRPD peaks as per FIG. 8B; and/or DSC spectrum as per FIG. 8C; (xix) Crystalline hydrogen L(+)tartrate salt (31f), with a XRPD spectrum as per FIG. 9A; XRPD peaks as per FIG. 9B; DSC spectrum as per FIG. 9C; (xx) Crystalline D,L-mandelate salt (31g), with a XRPD spectrum as per FIG. 10A; XRPD peaks as per FIG. 10B; and/or DSC spectrum as per FIG. IOC; (xxi) Crystalline tosylate salt form Tos-A (31h-l), with a XRPD spectrum as per FIG. 11 A; XRPD peaks as per FIG. 11B; and/or DSC spectrum as per FIG. 11C; (xxii) Crystalline tosylate salt form Tos-B (31h-2), with a XRPD spectrum as per FIG. 12A; XRPD peaks as per FIG. 12B; and/or DSC spectrum as per FIG. 12C; (xxiii) Crystalline mesylate salt (31i), with a XRPD spectrum as per FIG. 13A; XRPD peaks as per FIG. 13B; and/or DSC spectrum as per FIG. 13C; (xxiv) Crystalline saccharinate salt (31j), with a XRPD spectrum as per FIG. 14A; XRPD peaks as per FIG. 14B; and/or DSC spectrum as per FIG. 14C; and any mixtures thereof. 14. A pharmaceutical composition comprising at least one compound of any of claims 1-4 and at least one pharmaceutically acceptable carrier or excipient. 15. The composition of claim 14, further comprising at least one additional agent selected from the group consisting of doxapram, enantiomers of doxapram, acetazolamide, almitrine, theophylline, caffeine, methylprogesterone and related compounds, sedatives that increase arousal threshold in sleep disordered breathing patients, benzodiazepine receptor agonists, orexin antagonists, tricyclic antidepressants, serotonergic modulators, adenosine and adenosine receptor and nucleoside transporter modulators, cannabinoids, orexins, melatonin agonists, ampakines, sodium oxybate, modafinil, and armodafinil. 16. The composition of claim 15, wherein the compound and the additional agent are physically mixed or physically separated in the composition. 17. The composition of claim 14, further comprising at least one additional agent that causes changes in breathing control. 18. The composition in claim 17, wherein the additional agent is at least one selected from the group consisting of opioid narcotics, benzodiazepines, sedatives, sleeping aids, hypnotics, propofol, and any combinations thereof. 19. The composition of claim 15 or 17, wherein the compound and the additional agent are physically mixed or physically separated in the composition. 20. The composition of claim 14, wherein the composition allows for modified delivery of the compound following oral administration to a subject. 21. The composition of claim 20, wherein the composition minimizes delivery of the compound to the stomach of the subject and maximizes delivery of the compound to the intestine of the subject. 22. The composition of claim 14, wherein the composition includes an enteric coating. 23. The composition of claim 14, wherein the compound is contained in a pharmaceutically suitable capsule. 24. The composition of claim 23, wherein the capsule contains granules or powder of the compound, or an admixture of the compound with the carrier or excipient. 25. The composition of claim 24, wherein the excipient comprises a binder, disintegrant, diluent, buffer, lubricant, glidant, antioxidant, antimicrobial preservative, colorant, or flavorant. 26. The composition of claim 24, wherein the capsule is enterically coated but the granules or powders of the compound are not enterically coated. 27. The composition of claim 24, wherein the granules or powders of the compound are coated with an enteric coating before being placed into the capsule. 28. The composition of claim 27, wherein the granules or powders of the compound are coated with a plurality of enteric coatings, as to provide delivery of drug to different regions of the intestine of the subject. 29. The composition of claim 24, wherein at least a portion of the granules or powders of the compound are enterically coated. 30. The composition of claim 24, wherein the capsule is coated with an enteric coating that is different from the enteric coating that coats the granules or powders of the compound. 31. The composition of claim 14, wherein the compound is coated onto a base particle so as to form a core. 32. The composition of claim 31, wherein the base particle is not enterically coated and the composition is contained in a pharmaceutically acceptable capsule that is enterically coated. 33. The composition of claim 31, wherein the core is coated with an enteric coating, thereby forming an enterically coated bead. 34. The composition of claim 33, wherein the enterically coated bead is contained in a pharmaceutically acceptable capsule. 35. The composition of claim 34, wherein the capsule contains beads coated with a plurality of enteric coatings, so that the capsule provides delivery of the compound to different regions of the intestine of the subject. 36. The composition of claim 34, wherein the contents of the capsule are dissolved or suspended in a pharmaceutically acceptable liquid as to provide a liquid-filled capsule. 37. The composition of claim 36, wherein the capsule is enterically coated but the liquid formulation contained within does not comprise an enteric coating. 38. A method of preventing or treating a breathing control disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of at least one compound of any of claims 1-4 or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof. 39. The method of claim 38, wherein the breathing control disorder or disease is at least one selected from the group consisting of respiratory depression, sleep apnea, apnea of prematurity, obesity -hypoventilation syndrome, primary alveolar hypoventilation syndrome, dyspnea, altitude sickness, hypoxia, hypercapnia, chronic obstructive pulmonary disease (COPD), sudden infant death syndrome (SIDS), congenital central hypoventilation syndrome, Alzheimer's disease, Parkinson's disease, stroke, Duchenne muscular dystrophy, and brain and spinal cord traumatic injury. 40. The method of claim 39, wherein the respiratory depression is caused by an anesthetic, a sedative, a sleeping aid, an anxiolytic agent, a hypnotic agent, alcohol or a narcotic. 41. The method of claim 38, wherein the subject is further administered at least one agent useful for treating the breathing disorder or disease. 42. The method of claim 41 , wherein the agent is at least one selected from the group consisting of doxapram, acetazolamide, almitrine, theophylline, caffeine, methylprogesterone and related compounds, sedatives that increase arousal threshold in sleep disordered breathing patients, benzodiazepine receptor agonists, orexin antagonists, tricyclic antidepressants, serotonergic modulators, adenosine and adenosine receptor and nucleoside transporter modulators, cannabinoids, orexins, melatonin agonists, ampakines, sodium oxybate, modafinil, and armodafinil. 43. The method of claim 41, wherein the compound and the agent are separately administered to the subject. 44. The method of claim 41, wherein the compound and the agent are coadministered to the subject, further wherein the compound and the agent are physically mixed or physically separated when administered to the subject. 45. The method of claim 38, wherein the subject is further administered at least one additional therapeutic agent that changes normal breathing control in the subject. 46. The method of claim 45, wherein that at least one additional agent is selected from the group consisting of opioid narcotics, benzodiazepines, sedatives, sleeping aids, hypnotics, propofol, and any combinations thereof. 47. The method of claim 38, wherein the compound is administered in conjunction with the use of a mechanical ventilation device or positive airway pressure device on the subject. 48. The method of claim 38, wherein the subject is a mammal or bird. 49. The method of claim 48, wherein the mammal is a human. 50. The method of claim 38, wherein the compound is administered to the subject by at least one route selected from the group consisting of nasal, inhalational, topical, oral, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intrathecal and intravenous routes. 51. The method of claim 38, wherein the at least one compound is selected from the group consisting of: 2-(2,6-Bis-methylainino-8-propylainino-pyrirnido[5,4-d]pyrirnidin-4-ylamin (4); 2- [(2,6-Bis-methylairrino-8-propylamino ethanol (6); 3- (2,6-Bis-methylairrino-8-propylairrino-pyri (8); 1- (2,6-Bis-methylairrino-8-propylairrino-pyrim (10); (S)-l -(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-propan-2- ol (12); (R)-l-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-propan- ol (14); 2- (2,6-Bis-methylairrino-8-propylairrino-pyrim propan-l-ol (16); (S)-2-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan ol (18); (R)-2-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan- 1- ol (20); 3- (2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-l, l, l - trifluoro-propan-2-ol (22); 1- (2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-butan-2-ol (24); 3-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-butan-2-ol (26); 2- (2,6-Bis-ethylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-ethanol (27); 2-[8-Propylamino-2,6-bis-(2,2,2 rifluoro-ethylamino)-pyrimido[5,4-d]pyrimidin-4-ylami ethanol (28); l-(2,6-Bis-methylairrino-8-propylairrino-pyri propan-2-ol (31); l-(2,6-Bis-ethylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-2-methyl- propan-2-ol (32); 1- [2,6-Bis-(2,2-difluoro-ethylamino)-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylam 2- methyl-propan-2-ol (33); 2- Methyl-l -[8-propylairrino-2,6-bis-(2,2,2 rifl ylamino]-propan-2-ol (34); l -[8-(2,2-difluoro-ethylamino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-^ 2-methyl-propan-2-ol (36) l-{2,6-bis-methylamino-8-[(pyrimidin-2-ylmethyl)-amino]-pyrimido[5,4-d]pyri ylamino}-2-methyl-propan-2-ol (38) l-[8-((R)- ,ec-butylamino)-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylami methyl-propan-2-ol (40) l-[8-((S)- ,ec-butylamino)-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino]-2- methyl-propan-2-ol (42) l-(8-benzylamino-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-2-methyl- propan-2-ol (44) l-[8-(cyclopropylmethyl-amino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylami 2-methyl-propan-2-ol (46) 1- [8-(2,2-difluoro-ethylamino)-2,6-bis-ethylamino-pyrimido[5,4-d]pyrimidin-4-ylamino]^ methyl-propan-2-ol (47) 2- methyl-l-(2,6,8 ris-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-2-ol (48) 2-methyl-l-(2,6,8 ris-ethylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-2-ol (49) 2-(2,6,8-tris-methylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-ethanol (52) 2-[8-(cyclopropylmethyl-amino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylami ethanol (54) 2-[8-(2-methoxy-ethylamino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylami ethanol (56) 2-(2,6-bis-methylairrino-8-prop-2-ynylairrin^ (58) 2-[8-(2,2-difluoro-ethylamino)-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylam ethanol (60) 2-[2,6-bis-methylamino-8-(2,2,2 rifluoro-ethylamino)-pyrimido[5,4-d]pyrimidin-4- ylamino] -ethanol (62) 2- (8-benzylamino-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-ethanol (64) 3- (8-ethylamino-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-l^ (67) l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl)-pyrrolidin-3 (71) l-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-me cyclobutanol (72) l-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-yl)-methyl-am propan-2-ol (73) 3-[(2,6-bis-methylairrino-8-propylairrino pentan-3-ol (74) 1- [(2,6-bis-methylairrino-8-propylairrino methyl-propan-2-ol (76) (lR,2S)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino indan-2-ol (77) (l S,2S)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)- indan-2-ol (78) (l S,2R)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- indan-2-ol (79) (lR,2R)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)- indan-2-ol (80) (2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-indan-l-ol (81) (lR,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclohexanol (82) (l S,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclohexanol (83) (l S,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclohexanol (84) (lR,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclohexanol (85) (l S,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclopentanol (86) (lR,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclopentanol (87) 2- [6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylami ethanol (90) 2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-ethanol (91) 2-(6-dimethylairrino-4,8-bis-methylamin^ (92) l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-2-methyl- propan-2-ol (94) l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-propan-2-o (95) l-[(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-yl)-methyl-am methyl-propan-2-ol (96) l-[(4,8-bis-methylairrino-6-propylairrino propan-2-ol (97) l-[6-((R)-sec-butylairrino)-4,8-bis-methyl^ methyl-propan-2-ol (99) (R)-l-[6-((R)-sec-butylamino)-4,8-bis-methyla propan-2-ol (100) (S)-l-[6-((R)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]- propan-2-ol (101) l-[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino]-2- methyl-propan-2-ol (103) (R)-l-[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]- propan-2-ol (104) (S)-l-[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]- propan-2-ol (105) l-[6-(2,2-difluoro-ethylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylam 2-methyl-propan-2-ol (107) l-{4,8-bis-methylairrino-6-[(pyrirrridin-2-ylm ylamino}-2-methyl-propan-2-ol (109) 3-(4,8-bis-methylairrino-6-propylairrino-pyrirm^ propan-2-ol (111) (S)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2- ol (113) (R)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2- ol (115) l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2-ol (117) 3-(4,8-Bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2-ol (119) (lR,2S)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)- indan-2-ol (123) (lS,2S)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)- indan-2-ol (125) (l S,2R)-l-(4,8-bis-methylairrino-6-propylairrino indan-2-ol (127) (lR,2R)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)- indan-2-ol (129) (lR,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (131) (l S,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (133) (l S,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (135) (lR,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (137) (l S,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclopentanol (139) (lR,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclopentanol (141) (S)-l-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2- ylamino]-propan-2-ol (142) (S)-l-(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (143) (R)-l-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2- ylamino]-propan-2-ol (144) (R)-l-(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2- (145) l-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylami butan-2-ol (146) 1- (6-ethylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2- (147) 2- methyl-l-(4,6,84ris-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (149) 2-(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-ethanol (154) (S)-l-[(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-yl)-propyl-ami propan-2-ol (155) (S)-l-[(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-yl)-methyl-ami propan-2-ol (156) (R)-l-[6-(2-methyl-allylainino)-4,8-bis-methylam propan-2-ol (158) (S)-l-[6-(2-methyl-allylainino)-4,8-bis-m propan-2-ol (159) 2-(4,8-bis-ethylamino-6-propylamino-pyrirn ^ (162) l-(4,8-bis-ethylainino-6-propylainino-pyri propan-2-ol (163) (S)-l-(4,6,8-Tris-ethylanTino-pyrinTido[5,4-d]pyrinTidin-2-ylamino)-propan-2-ol (165) (S)-l-(4,8-bis-ethylairdno-6-propyland^ (166) (R) -L (4,6,8-risk ethylanTino-pyrinTido [5,4-d] pyrinTidin-2-ylamino) -propan-2-ol (168) (R)-l-(4,8-bis-ethylairrino-6-propylanri^ (169) (R)-l-[4,8-bis-ethylainino-6-(2-methyl-allylaim^ propan-2-ol (174) (S)-l-[4,8-bis-ethylainino-6-(2-methyl-allylainm^ propan-2-ol (175) a salt, solvate, enantiomer, diastereoisomer or tautomer thereof; and any combinations thereof. 52. The method of claim 38, wherein the salt comprises an acid addition salt, and the acid is at least one selected from the group consisting of sulfuric, hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, phosphoric, formic, acetic, propionic, succinic, gly colic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, pamoic, methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, sulfanilic, stearic, alginic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, />-toluenesulfonic, cyclohexylaminosulfonic, β-hydroxybutyric, salicylic, galactaric and galacturonic, and any combinations thereof. 53. A method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, the method comprising administering to the subject an effective amount of at least one pharmaceutically acceptable carrier and at least one compound of any of claims 1-4, or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof. 54. The method of claim 53, wherein the destabilization is associated with a breathing control disorder or disease selected from the group consisting of respiratory depression, sleep apnea, apnea of prematurity, obesity-hypoventilation syndrome, primary alveolar hypoventilation syndrome, dyspnea, altitude sickness, hypoxia, hypercapnia, chronic obstructive pulmonary disease (COPD), sudden infant death syndrome (SIDS), congenital central hypoventilation syndrome, Alzheimer's disease, Parkinson's disease, stroke, Duchenne muscular dystrophy, and brain and spinal cord traumatic injury. 55. The method of claim 54, wherein the respiratory depression is caused by an anesthetic, a sedative, a sleeping aid, an anxiolytic agent, a hypnotic agent, alcohol or a narcotic. 56. The method of claim 53, wherein the subject is further administered at least one agent useful for treating the breathing disorder or disease. 57. The method of claim 56, wherein the agent is selected from the group consisting of doxapram, acetazolamide, almitrine, theophylline, caffeine, methylprogesterone and related compounds, sedatives that increase arousal threshold in sleep disordered breathing patients, benzodiazepine receptor agonists, orexin antagonists, tricyclic antidepressants, serotonergic modulators, adenosine and adenosine receptor and nucleoside transporter modulators, cannabinoids, orexins, melatonin agonists, ampakines, sodium oxybate, modafinil, and armodafinil. 58. The method of claim 56, wherein the compound and the agent are separately administered to the subj ect. 59. The method of claim 56, wherein the compound and the agent are coadministered to the subject, further wherein the compound and the agent are physically mixed or physically separated when administered to the subject. 60. The method of claim 53, wherein the subject is further administered at least one additional therapeutic agent that changes normal breathing control in the subject. 61. The method of claim 60, wherein the additional agent is at least one selected from the group consisting of opioid narcotics, benzodiazepines, sedatives, sleeping aids, hypnotics, propofol, and any combinations thereof. 62. The method of claim 53, wherein the compound is administered in conjunction with the use of a mechanical ventilation device or positive airway pressure device on the subject. 63. The method of claim 53, wherein the subject is a mammal or bird. 64. The method of claim 53, wherein the compound is administered to the subject by at least one route selected from the group consisting of nasal, inhalational, topical, oral, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intrathecal and intravenous routes. 65. The method of claim 53, wherein the compound is selected from the group consisting of: 2-(2,6-Bis-methylamino-8-propylainino-pyrirnido[5,4-d]pyrirnidin-4-ylamin (4); 2- [(2,6-Bis-methylamino-8-propylamino-pyrirnido[5,4-d]pyrirnidin-4-yl)-methyl-ami ethanol (6); 3- (2,6-Bis-methylamino-8-propylainino-pyrirnido[5,4-d]pyrirnidin-4-ylamino)-propa^ (8); 1- (2,6-Bis-methylamino-8-propylainino-pyrirnido[5,4-d]-pyrirnidin-4-ylami (10); (S)-l -(2,6-Bis-methylamino-8-propylainino-pyrirnido[5,4-d]pyrirnidin-4-ylamin ol (12); (R)-l-(2,6-Bis-methylamino-8-propylainino-pyrimido[5,4-d]pyrirnidin-4-ylamino)-p ol (14); 2- (2,6-Bis-methylamino-8-propylainino-pyrirnido[5,4-d]-pyrirnidin-4-ylamino) propan-l-ol (16); (S)-2-(2,6-Bis-methylamino-8-propylainino-pyrirnido[5,4-d]-pyrirnidin-4-ylanTi ol (18); (R)-2-(2,6-Bis-methylamino-8-propylainino-pyrirnido[5,4-d]-pyrirnidin-4-ylarmn l-ol (20); 3-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-l, l, l - trifluoro-propan-2-ol (22); 1- (2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-butan-2-ol (24); 3-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-butan-2-ol (26); 2- (2,6-Bis-ethylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-ethanol (27); 2-[8-Propylamino-2,6-bis-(2,2,2 rifluoro-ethylamino)-pyrimido[5,4-d]pyrimidin-4-ylami ethanol (28); l-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-2-methyl- propan-2-ol (31); l-(2,6-Bis-ethylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-2-methyl- propan-2-ol (32); 1- [2,6-Bis-(2,2-difluoro-ethylamino)-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino]- 2-methyl-propan-2-ol (33); 2- Methyl-l -[8-propylairrino-2,6-bis-(2,2,2-trifl^ ylamino]-propan-2-ol (34); l -[8-(2,2-difluoro-ethylamino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylam 2-methyl-propan-2-ol (36) l - {2,6-bis-methylamino-8-[(pyrimidin-2-ylmethyl)-amino]-pyrimido[5,4-d]pyrimidm ylamino}-2-methyl-propan-2-ol (38) l -[8-((R)- ,ec-butylamino)-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamin^ methyl-propan-2-ol (40) l -[8-((S)- ,ec-butylamino)-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino]-2- methyl-propan-2-ol (42) l -(8-benzylamino-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-2-methyl- propan-2-ol (44) l -[8-(cyclopropylmethyl-amino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-ylami 2-methyl-propan-2-ol (46) 1 - [8-(2,2-difluoro-ethylamino)-2,6-bis-ethylamino-pyrimido[5,4-d]pyrimidin-4-ylamino]^ methyl-propan-2-ol (47) 2- methyl-l -(2,6,8 ris-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-2-ol (48) 2-methyl-l -(2,6,8 ris-ethylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-2-ol (49) 2-(2,6,8-tris-methylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-ethanol (52) 2-[8-(cyclopropylmethyl-amino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-^ ethanol (54) 2-[8-(2-methoxy-ethylamino)-2,6-bis-methylamino-pyrimido[5,4-d]pyrimidin-4-y ethanol (56) 2-(2,6-bis-methylainino-8-prop-2-ynylainino-pyrim (58) 2-[8-(2,2-difluoro-ethylamino)-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylam ethanol (60) 2-[2,6-bis-methylamino-8-(2,2,2 rifluoro-ethylamino)-pyrimido[5,4-d]pyrimidin-4- ylamino] -ethanol (62) 2- (8-benzylamino-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-ethanol (64) 3- (8-ethylamino-2,6-bis-methylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-propan-l-o (67) l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl)-pyrrolidin-3 (71) l-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-met^^ cyclobutanol (72) l-[(2,6-bis-methylainino-8-propylainino-pyri propan-2-ol (73) 3-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)-me&^ pentan-3-ol (74) l-[(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl)-methyl-am methyl-propan-2-ol (76) (lR,2S)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylami indan-2-ol (77) (l S,2S)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)- indan-2-ol (78) (l S,2R)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylami indan-2-ol (79) (lR,2R)-l-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)- indan-2-ol (80) (2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]-pyrimidin-4-ylamino)-inda^ (81) (lR,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino cyclohexanol (82) (l S,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclohexanol (83) (l S,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclohexanol (84) (lR,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclohexanol (85) (l S,2S)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclopentanol (86) (lR,2R)-2-(2,6-bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-ylamino)- cyclopentanol (87) 2-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylami ethanol (90) 2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-ethanol (91) 2-(6-dimethylamino-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-etha^ (92) l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-2-methyl- propan-2-ol (94) l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-propan-2-o (95) l-[(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-yl)-methyl-amino]- methyl-propan-2-ol (96) l-[(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-yl)-methyl-amino]- propan-2-ol (97) l-[6-((R)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino methyl-propan-2-ol (99) (R)-l-[6-((R)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylam propan-2-ol (100) (S)-l-[6-((R)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]- propan-2-ol (101) l-[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino]-2- methyl-propan-2-ol (103) (R)-l-[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]- propan-2-ol (104) (S)-l-[6-((S)- ,ec-butylamino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino]- propan-2-ol (105) l-[6-(2,2-difluoro-ethylairrino)-4,8-bis-m 2-methyl-propan-2-ol (107) l-{4,8-bis-methylairrino-6-[(pyrirrridin-2-ylm ylamino}-2-methyl-propan-2-ol (109) 3-(4,8-bis-methylairrino-6-propylairrino-pyrim propan-2-ol (111) (S)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2- ol (113) (R)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2^ ol (115) l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2-ol (117) 3-(4,8-Bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2-ol (119) (lR,2S)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)- indan-2-ol (123) (l S,2S)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)- indan-2-ol (125) (l S,2R)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)- indan-2-ol (127) (lR,2R)-l-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)- indan-2-ol (129) (lR,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (131) (l S,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (133) (l S,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (135) (lR,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclohexanol (137) (l S,2S)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclopentanol (139) (lR,2R)-2-(4,8-bis-methylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)- cyclopentanol (141) (S)-l -[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2 ylamino]-propan-2-ol (142) (S)-l -(6-allylairrino-4,8-bis-methylamino-pyri^ (143) (R)-l-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2- ylamino]-propan-2-ol (144) (R)-l-(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan^ (145) l-[6-(cyclopropylmethyl-amino)-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylami butan-2-ol (146) 1- (6-ethylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-butan-2- (147) 2- methyl-l -(4,6,84ris-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (149) 2-(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-ethanol (154) (S)-l -[(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-yl)-propyl-am propan-2-ol (155) (S)-l -[(6-allylamino-4,8-bis-methylamino-pyrimido[5,4-d]pyrimidin-2-yl)-methyl-ami propan-2-ol (156) (R)-l-[6-(2-methyl-allylamino)-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylami propan-2-ol (158) (S)-l -[6-(2-methyl-allylamino)-4,8-bis-methylamino-pyrimido[5,4-d]-pyrimidin-2-ylam propan-2-ol (159) 2-(4,8-bis-ethylamino-6-propylamno-pyrimido[5,4-d]pyrimidin-2-ylamino)-ethanol (162) l-(4,8-bis-ethylamino-6-propylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-2-methyl- propan-2-ol (163) (S)-l -(4,6,8-Tris-ethylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (165) (S)-l -(4,8-bis-ethylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-propan-2-ol (166) (R)-l-(4,6,8 ris-ethylamino-pyrimido[5,4-d]pyrimidin-2-ylamino)-propan-2-ol (168) (R)-l-(4,8-bis-ethylamino-6-propylamino-pyrimido[5,4-d]-pyrimidin-2-ylamino)-propan-2-ol (169) (R)-l -[4,8-bis-ethylamino-6-(2-methyl-allylamino)-pyrimido[5,4-d]-pyrimidin-2-ylamino] propan-2-ol (174) (S)-l -[4,8-bis-ethylamino-6-(2-methyl-allylamino)-pyrimido[5,4-d]-pyrimidin-2-ylamino]- propan-2-ol (175) a salt, solvate, enantiomer, diastereoisomer or tautomer thereof; and any combinations thereof. 66. The method of claim 53, wherein the salt comprises an acid addition salt, and the acid is at least one selected from the group consisting of sulfuric, hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, phosphoric, formic, acetic, propionic, succinic, gly colic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, pamoic, methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, sulfanilic, stearic, alginic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, />-toluenesulfonic, cyclohexylaminosulfonic, β-hydroxybutyric, salicylic, galactaric and galacturonic, and any combinations thereof.